Overview
- The company executed an upsized equity sale that raised roughly $20 billion and priced near $95 per share, with JPMorgan, Goldman Sachs, Morgan Stanley and Citigroup serving as joint book‑runners.
- Net proceeds will be used for general corporate purposes with a clear focus on capital expenditures to expand advanced-node fabs, packaging lines and external wafer capacity as Intel scales its foundry business.
- Underwriters have a 30‑day option to buy up to $2.25 billion of additional shares and institutional demand was reported as very strong, producing heavy oversubscription even after an initial premarket share drop on dilution concerns.
- The raise builds on prior strategic investments that include the U.S. government’s 9.9% CHIPS Act stake and private placements from Nvidia and SoftBank, and it follows signs of customer traction such as Tesla’s confirmed use of Intel’s 14A node while reports that Apple may be interested remain unconfirmed.
- Key risks to watch are timely execution of multi‑year, expensive fabs, the challenge of turning added capacity into profitable external foundry revenue in the face of TSMC competition, and how the larger capex trajectory will affect margins and shareholder dilution over 2027 and beyond.